Introduction
Subarachnoid hemorrhage (SAH), a fetal cerebrovascular disease with high morbidity and mortality rates, is usually associated with long-term poor outcome. 1 Our current understanding is that early brain injury (EBI) is considered to refer to direct brain damage occurring after SAH. 2 Therefore, the elimination of EBI is becoming an important alternative therapy for SAH. Increasing evidence indicates that neural apoptosis, a key submit your manuscript | www.dovepress.com
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process in the pathogenesis of EBI after SAH, has become a key target in the prevention of brain cell death. 3, 4 Despite the development of some antiapoptotic strategies for SAH, current therapeutic strategies remain unsatisfactory and we still know little about the molecular mechanisms involved.
Tumor necrosis factor-alpha (TNF-α), a cytokine involved in neuronal inflammation, apoptosis and necrosis, is known to be upregulated in both the cerebral cortex and hippocampus after SAH. 5 A previous study showed that apoptotic cell death, overlapping with inflammation, could further strengthen the interactions between distinct mediators of brain injury after SAH. 6 Inhibition of TNF-α has been approved for therapeutic use in a range of inflammatory disorders, including Crohn's disease, rheumatoid arthritis, spondyloarthritis and psoriasis. 7, 8 Our previous study confirmed that the functional blockade of TNF-α could prevent apoptosis-associated gene expression in the hippocampus and prefrontal cortex after SAH, suggesting that TNF-α could represent a potential therapeutic target for acute brain injury in SAH-induced apoptosis in these brain regions. 9 This was the first study, to our knowledge, to show the therapeutic effect of anti-TNF-α antibody in SAH. However, the potential molecular mechanisms underlying the inhibition of SAH-induced apoptosis by anti-TNF-α antibody need to be further elucidated.
Treatment with anti-TNF-α agents could modulate the expression levels of a number of genes. Previous experiments have demonstrated that anti-TNF-α-neutralizing antibody reduced apoptosis in podocytes in diabetic nephropathy by inhibiting the activation of mitogen-activated protein kinases. 10 Interestingly, studies have shown that extracellular signal-regulated kinase (Erk), the downstream signaling molecule of mitogen-activated protein kinases, is aberrantly upregulated during neuronal apoptosis induced by SAH, cerebral ischemia, stroke and neurodegenerative diseases. [11] [12] [13] Furthermore, blocking the activation of Erk using an Erk inhibitor, dominant-negative or constitutively active forms of Erk, has been confirmed to prevent the induction of apoptosis. [14] [15] [16] However, it remains unknown as to whether the effect of anti-TNF-α antibody upon apoptosis induced by SAH is related to Erk activation or not.
Interestingly, numerous reports have demonstrated regional specificity in both the pathology and pharmacology of the central neural system. 17, 18 In particular, apoptotic changes have been detected in most brain regions in animal models of SAH, especially in the basal cortex and hippocampus. 19 Recent studies have begun to highlight the role of the hypothalamus in brain injury and have shown that traumatic brain injury can induce apoptosis in the hypothalamus. 20 Furthermore, SAH may lead to dysfunction of the hypothalamus. 21 However, thus far, very few studies have investigated whether SAH could lead to apoptosis in the hypothalamus. Since hypothalamus is involved in regulating homeostasis, motivation and emotional behavior, 22 elucidating the apoptotic pathway in the hypothalamus and developing appropriate neuroprotective strategies will be highly desirable in the treatment of SAH. Taken together, in this study, we investigated the effect of anti-TNF-α antibody on SAH-induced apoptosis in the hypothalamus of rats, as well as the potential molecule mechanisms involved.
Materials and methods
Male Wistar rats (250-350 g, N=153) were used throughout this study. The flow diagram of the study is shown in Figure 1 . All animals were treated humanely in accordance with the guidelines for the Care and Use of laboratory Animals by the National Institute of Health, and the study was approved by the Animal Care and Use Committee of the Second Hospital of Shandong University.
an animal model of sah
The SAH procedure was performed as described in our previous study. 9 In brief, male Wistar rats were anesthetized by an intraperitoneal injection of 5% chloral hydrate (0.75 mL/100 g). The left femoral artery was exposed, and 0.3 mL of fresh non-heparinized blood was withdrawn using a 27-gauge needle. Then, the artery was ligated at the proximal area. The head of the rats was then positioned in a stereotaxic apparatus. The arch of the atlas, occipital bone and atlanto-occipital membrane were exposed with a small suboccipital incision. Then, the fresh non-heparinized blood (0.3 mL) from the autologous femoral artery was injected into the cisterna magna at a rate of 0.05 mL/min using a 27-gauge infusion cannula connected to a microsyringe pump. After the induction of SAH, rats were kept in a head-down position until they awoke from the anesthesia, to ensure adequate subarachnoid distribution of the injected blood. The same operation was repeated 48 h later. After surgery, the rats were returned to the cages for recovery.
Drug treatment
For intracerebroventricular microinfusion, animals were placed in a stereotaxic apparatus (RWD Life Science Co., Ltd, 8001, Shenzhen, China) with the bregma used as the zero point. The left lateral cerebral ventricle was entered by using the following coordinates: anteroposterior, -0. To examine the time course of apoptotic gene expression in the hypothalamus after SAH, rats were sacrificed at day 1, day 2 and day 7, respectively. For the animals infused with anti-TNF-α antibody or the same volume of PBS, rats were killed 48 h (day 2) after SAH surgery. As a control, the sham-operated rats were sacrificed from their home cages. The hypothalamus was dissected out from each rat and RNA was extracted using the Ultrapure RNA Kit (CW Biotech, CW0597S, Beijing, China), in accordance with the manufacturer's instructions. In brief, fresh or frozen samples (-70°C) were first cut into small tissue fragments. Then, 30-50 mg of tissue was added to 1 mL TRIzol reagent homogenized and then incubated for 5 min at room temperature. To each homogenate, a 1/5 volume 
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Ma et al of chloroform was added and the mixture was vortex mixed and centrifuged at the maximum speed for 10 min at 4°C. The upper aqueous phase was removed and placed into a new tube. The same volume of 70% ethanol (RNase-free) was added and the resulting solution was transferred into a spin column with a collection tube and then centrifuged at 12,000 rpm for ~20 s. The solution in the collection tube was discarded and the spin column was washed three times with wash buffer. After drying out at room temperature, RNA was then dissolved with 30-50 μL of fresh RNase-free water.
Then 0.5 μg of total RNA was reverse transcribed into cDNA using the PrimeScript™ RT Reagent Kit (Takara, RR037A, Otsu, Japan). Real-time PCRs of cDNA samples were performed in a total volume of 20 μL with SYBR (Takara, RR086A), primers at 800 nM and 2 μL of DNA template. The primer sequences used for PCR amplification were as follows: 5′ TGT GGA TGA CTG AGT ACC TGA ACC 3′ and 5′ CAG CCA GGA GAA ATC AAA CAG AGG 3′ forward and reverse primers for bcl-2; 5′ CGG CGA ATT GGA GAT GAA CTG G 3′ and 5′ CTA GCA AAG TAG AAG AGG GCA ACC 3′ forward and reverse primers for bax; 5′ GTG GAA CTG ACG ATG ATA TGG C 3′ and 5′ CGC AAA GTG ACT GGA TGA ACC 3′ forward and reverse primers for caspase-3; 5′ GGA GAT TAC TGC CCT GGC TCC TA 3′ and 5′ GAC TCA TCG TAC TCC TGC TTG CTG 3′ forward and reverse primers for β-actin. Quantitative real-time PCR was performed in a LightCycler2.0 (Roche, Basel, Switzerland). Thermal cycler parameters included 30 s at 95°C, and 40 cycles of denaturation at 95°C for 5 s, annealing at 62°C for 5 s and extension at 72°C for 10 s. The mRNA levels of target genes were normalized for each well to the mRNA levels of the housekeeping gene β-actin using the 2 -ΔΔCT method. 23 
Western blotting
Rats under different treatments were killed 48 h after SAH. The hypothalamus was dissected from each rat and homogenized in RadioImmunoPrecipitation Assay buffer consisting of 10 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 1 mM EDTA pH 8.0 and 10% glycerol with protease inhibitors. Protein lysates, mixed with sodium dodecyl sulfate sample buffer, were boiled for 5 min. Protein concentration was then measured using a BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Next, 30 μg of protein was loaded in each lane and separated in a 10% sodium dodecyl sulfate-polyacrylamide gel and then transferred to a polyvinylidene difluoride membrane. Blots were blocked with 5% non-fat dry milk in PBS for 2 h at room temperature.
Subsequently, the blots were separately incubated overnight at 4°C with the following antibodies: rabbit anti-caspase-3 (1:1,000; Cell Signaling Technology, #9665, Danvers, MA, USA), rabbit anti-bax (1:1,000; Cell Signaling Technology, #2772), rabbit anti-bcl-2 (1:1,000; Cell Signaling Technology, #2870), rabbit anti-phosphorylated Erk (p-Erk, 1:2,000; Cell Signaling Technology, #4370), rabbit anti-Erk (1:2,000; Cell Signaling Technology, #4695), rabbit anti-TNF-α (1:1,000; R&D Systems, AF-510-SP, Minneapolis, MN, USA) or rabbit anti-β-actin (1:1,000, as a control; Cell Signaling Technology, #4970). After the blots were washed with PBS for three times, they were incubated with horse radish peroxidase-conjugated secondary antibodies (1:5,000; Cell Signaling Technology, #7074) for 2 h at room temperature. Finally, Western blot signals were detected using the enhanced chemiluminescence system (EMD Millipore, WBKLS0100, Billerica, MA, USA). Scanned images were visualized with ImageJ software.
immunohistochemistry
For immunohistochemistry, rats from each group (microinfused with anti-TNF-α antibody, microinfused with PBS or sham-operated rats) were anesthetized by an intraperitoneal injection of 5% chloral hydrate (0.75 mL/100 g) 48 h after SAH. Rats were then perfused transcardially with 0.9% saline followed by 4% paraformaldehyde. Brains were removed and post-fixed in 4% paraformaldehyde overnight, and then equilibrated in 30% sucrose/PBS at 4°C for at least 3 days. Brains were then coronally sectioned at 20 μm thickness with a cryotome. Sections were washed with PBS three times and then blocked in 10% normal goat serum/PBS/0.3% Triton X-100 for 2 h at room temperature. Next, the sections were incubated overnight at 4°C with polyclonal anti-caspase-3 (1:100; Bioworld Technology, Louis Park, MN, USA), antibax (1:50, Bioworld Technology) or anti-bcl-2 (1:50, Bioworld Technology). After washing three times in PBS, the sections were then incubated with biotinylated goat antirabbit antibody (Elite Kit; Vector Laboratories, Burlingame, CA, USA) for 2 h at room temperature. Staining was detected with a biotin-streptavidin amplification system. Fluorescence images were acquired using a Nikon 80i microscope configured with a charge-coupled device camera interfaced to a personal computer.
Open field
The open field apparatus consisted of a 100×100×50 cm wooden cube with a white floor, which was divided into 5×5 identical squares. Experiments were recorded using a video anti-TNF-α antibody and sah-induced apoptosis
camera above the open-field arena in a dim room, which was connected to a video recorder. Rats were placed in the center of the open field and allowed to explore for 10 min. The apparatus was cleaned with a 50% ethanol solution prior to the introduction of each animal. The total traveled distance and the time spent in the inner 4×4 squares were recorded to allow us to investigate anxiety-like behavior.
statistical analysis
Data were analyzed using the Student's t-test or one-way analysis of variance (ANOVA) followed by least significant difference post hoc comparisons. The significance level was set to 0.05 for all statistical analyses, and data were presented as mean ± standard error of the mean. Data analyses were performed using SPSS statistical program version 17.0.
Results
Time course of apoptotic-related gene expression following sah in the hypothalamus
To assess whether SAH could induce apoptosis in hypothalamus, we used real-time PCR to investigate the expression levels of apoptotic-related genes at various time-points, including caspase-3, bax and bcl-2. Gene expression levels were increased after SAH, not only for apoptotic molecules, such as caspase-3 (ANOVA: F (3, 21) =8.221, p=0.001; Figure 2A ) and bax (ANOVA: F (3, 20) =3.480, p=0.035; Figure 2B ), but also for the antiapoptotic molecule, bcl-2 (ANOVA: F (3, 19) =6.928, p=0.002; Figure 2C ). mRNA levels of caspase-3 increased from 24 h after SAH and peaked at 48 h. Compared with the temporal changes in caspase-3 mRNA levels, bcl-2 and bax mRNA showed a delayed increase, with both beginning to show increased mRNA levels 48 h after SAH. The observed temporal changes in these molecules suggest that SAH induced both apoptotic and antiapoptotic pathways in the hypothalamus.
Blockade of TNF-α can inhibit apoptosis induced by sah in the hypothalamus
Previous studies have shown that when treating brain disorders, the effects of drugs are inconsistent in different brain regions. Our previous study confirmed that anti-TNF-α antibody could inhibit apoptosis in the prefrontal cortex and hippocampus. 9 To investigate whether TNF-α is involved in apoptosis in the hypothalamus, rats in this study were divided into three groups: control group, PBS group 
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Ma et al and TNF-α antibody group. Rats received an infusion of anti-TNF-α antibody or the same volume of PBS and were killed 48 h after SAH surgery. The sham-operated control rats were sacrificed from their home cages. We initially observed changes in TNF-α protein in the hypothalamus by Western blotting. As Figure 3A shows, the expression of TNF-α increased 48 h after SAH, suggesting the induction of TNF-α synthesis by SAH in the hypothalamus. In addition, injection of anti-TNF-α antibody could sufficiently block SAH-induced TNF-α increase (ANOVA: F (2, 18) =4.592, p=0.024; Figure 3A) .
Next, to assess the effect of anti-TNF-α antibody upon SAH-induced apoptosis, we observed changes in the gene expression of caspase-3, bax and bcl-2 at 48 h after SAH. Compared with the PBS group, real-time PCR analysis showed that the microinfusion of anti-TNF-α antibody abolished increased bax mRNA levels in the hypothalamus (ANOVA: F (2,16) =10.406, p=0.001; Figure 3B ), but not the expression levels of caspase-3 (ANOVA: F (2, 17) =6.448, p=0.008; Figure 3B ) and bcl-2 (ANOVA: F (2, 12) =4.512, p=0.035; Figure 3B ).
Similar to the changes in mRNA levels, Western blot analysis showed increased expression of caspase-3, bax and bcl-2 protein levels in the hypothalamus in PBS-treated SAH rats relative to sham-operated controls 48 h after SAH. In addition, the infusion of anti-TNF-α antibody effectively suppressed increased levels of bax protein in the hypothalamus (ANOVA: F (2,23) =4.810, p=0.018; Figure 3D ), but not caspase-3 (ANOVA: F (2, 18) =4.543, p=0.025; Figure 3C ) or bcl-2 (ANOVA: F (2, 21) =6.834, p=0.005; Figure 3E ). Furthermore, immunohistochemistry revealed that the numbers of caspase-3-, bax-and bcl-2-positive cells were significantly increased in the hypothalamus 48 h after SAH, as compared to the sham group (Figure 4) . The elevated expression of bax, but not caspase-3 and bcl-2, was attenuated by blocking TNF-α in the hypothalamus (Figure 4 ), which strongly 
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anti-TNF-α antibody and sah-induced apoptosis confirmed the Western blotting data. It has been shown that the overall ratio of pro-to antiapoptotic signals determines whether or not cells die. 24 The inhibition of bax, but not bcl-2, suggests that anti-TNF-α antibody blocks the SAH-induced apoptosis in the hypothalamus. Together, these results further indicate that anti-TNF-α antibody can block apoptosis induced by SAH in the hypothalamus following selective inhibition of bax expression.
Blockade of TNF-α can inhibit the increased expression of p-erk in the hypothalamus
Previous research has shown that inhibition of Erk activation can reduce hippocampal neuronal apoptosis following SAH. 13 Next, we wanted to investigate whether the effect of anti-TNF-α antibody on SAH-induced apoptosis was due to regulating p-Erk levels. To address this, we initially examined whether Erk activation was required for apoptosis in the hypothalamus. Rats were divided into three groups: control group, vehicle group and U0126 group. U0126, a specific Erk inhibitor, or the same volume of vehicle was microinjected and then rats were sacrificed 48 h after SAH. As shown in Figure 5A , quantitative densitometric analyses showed elevated p-Erk levels in the hypothalamus of the vehicle group. However, this elevation was significantly reduced by the microinjection of U0126 (ANOVA: F (2,12) =4.815, p=0.029; Figure 5A and B). In addition, administration of U0126 could eliminate the SAH-induced upregulation of bax levels (ANOVA: F (2,12) =4.005, p=0.047; Figure 5A and B), which suggests that increased Erk activation is necessary for SAH-induced apoptosis. Furthermore, we found that the microinjection of anti-TNF-α antibody could prevent Erk activation 48 h after SAH, as compared with the vehicle group ( Figure 5C ). This inhibition could be reversed by the co-injection of PMA, a potent agonist of protein kinase C and its downstream effectors in the MEK/ERK-dependent pathway 25 (ANOVA: F (3, 16) =25.02, p0.001; Figure 5C and D). Additionally, bax was significantly elevated in response to PMA treatment, as compared with only anti-TNF-α antibody injection (ANOVA: F (3, 16) =9.066, p=0.001; Figure 5C and D), which further confirmed that p-Erk is not only necessary, but also sufficient for SAH-induced apoptosis. These results suggest that anti-TNF-α antibody can protect the hypothalamus against apoptosis by decreasing Erk phosphorylation.
Blockade of TNF-α can improve anxietylike behavior
Psychiatric disorders often develop after SAH, the most frequent of which are depression and depression-related disorders, including anxiety. Next, we determined if blockade of Figure 6A ) and 7 days after surgery (ANOVA: F (2, 21) =4.353, p=0.026; Figure 6A ). In addition, SAH rats with PBS injection showed decreased total traveled distance as compared with the control group both at 2 and 7 days after SAH. In contrast, no difference was found in the traveled distance between the control group and TNF-α antibody group (2 days, ANOVA: F (2, 21) =3.753, p=0.04; 7 days, ANOVA: F (2, 21) =4.090, p=0.032; Figure 6B ).
As the hypothalamus is involved in emotional behavior, these series of experiments suggest that the effect of anti-TNF-α antibody on improving anxiety-like behavior may be associated with the inhibition of apoptosis in the hypothalamus.
Discussion
The related molecular mechanisms underlying antiapoptotic strategies in the treatment of SAH are still not completely understood. In this study, we found that SAH induced apoptotic and antiapoptotic pathways in the hypothalamus. Neutralizing TNF-α with an anti-TNF-α antibody was shown to inhibit apoptosis induced by SAH in the hypothalamus, which was related to a reduction in Erk activation. In addition, anti-TNF-α antibody ameliorated SAH-induced anxiety-like behavior. Collectively, these results support the notion that TNF-α represents an effective target for the treatment of SAH-induced apoptosis in the hypothalamus. 
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Apoptosis plays a major role in the pathophysiological process of EBI, a condition that occurs rapidly after SAH. However, whether SAH can induce apoptosis in the hypothalamus is still unknown. Therefore, we considered that it was very important to explore the molecular mechanisms underlying apoptosis in the hypothalamus. Recent research has shown that intracranial hypertension, or global cerebral ischemia/reperfusion injury, can induce apoptosis of hypothalamic cells in rat models. 20, 26 Consistent with these previous reports, the data described herein showed increased expression levels of caspase-3 and bax in the hypothalamus after SAH, which suggests that SAH can induce apoptosis in the hypothalamus by caspase-3-and bax-dependent pathways. To our knowledge, this is the first study showing the SAH-induced apoptosis in the hypothalamus. Interestingly, our previous report showed that SAH increased the levels of caspase-3 and/or bax, but did not affect bcl-2 expression levels in the hippocampus and prefrontal cortex. 9 In a manner which was very different to the hippocampus and prefrontal cortex, the increased expression level of bcl-2 in the hypothalamus suggests that different molecular pathways are induced in selective brain regions during SAH-induced apoptosis. This result further confirms the regional specificity in the pathology of the central neural system after SAH. Because of the functional differences of these brain regions, it is not surprising to figure out that the apoptosis-related molecular pathways in various brain regions play different roles in the outcome of SAH.
Next, we showed that blockade of TNF-α can reverse the apoptosis induced by SAH in the hypothalamus via inhibiting the expression of specific apoptotic molecule.
Apoptosis can be regulated by inflammatory cytokines.
A previous study has demonstrated that inflammatory injury does, indeed, occur in the hypothalamus in global cerebral ischemia/reperfusion injury by determining TNF-α, IL-1β and IL-6 levels. 26 In our study, SAH stimulated the release of TNF-α in the hypothalamus, which suggests that TNF-α may plays a major role in SAH-induced apoptosis and inhibition of TNF-α is a potential therapeutic treatment for it. Although many selective inhibitors, such as caspase inhibitors, have been identified and can effectively protect cells from apoptosis, 27 the molecular mechanisms of inhibiting TNF-α are still not completely understood. An earlier study confirmed that TNF-α antibody strategy was useful for the treatment of acute injury to the central nervous system. 28 Moreover, our own previous study demonstrated that the use of anti-TNF-α antibody can protect rats from apoptosis by reducing the elevated levels of bax and/or caspase-3 in the hippocampus and prefrontal cortex, 9 suggesting a new therapeutic strategy for improving the outcome of SAH. In this study, we further confirmed that anti-TNF-α antibody could specifically suppress increased levels of bax in the hypothalamus after SAH, but not caspase-3. One recent study showed that TNF-α can mediate cell death by ligating its receptor TNF receptor 1 (TNFR1) and uptake of ligand-bound TNFR1 activates caspase-8 and -3 in cord blood monocytes. 29 The reduced levels of bax in this study suggest a different apoptosis pathway induced by TNF-α after SAH. Collectively, these results strongly suggest the differential molecular mechanisms of action for anti-TNF-α antibody in different brain regions during the inhibition of apoptosis after SAH.
α Figure 6 The effects of anti-TNF-α antibody on anxiety-like behavior. Notes: Rats were treated as described in Figure 3 . Open field analysis was performed on both days 2 and 7 after SAH. (A) Time spent in the center and (B) the total distance traveled were respectively recorded (n=8/group, *p0.05, **p0.01 versus sham-operated control group; 
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Ma et al Next, we showed that anti-TNF-α antibody could block the increased levels of p-Erk in the hypothalamus after SAH. Previous studies have shown that the Erk signaling pathway is a major determinant in controlling diverse cellular processes, including proliferation, migration, differentiation and apoptosis. [30] [31] [32] In addition, Erk activity has been confirmed to be involved in neurodegenerative diseases and ischemia stroke. 33 A recent study also reported that Erk plays a key proapoptotic role in the hippocampus in a rat model of SAH. 13 Consistent with these findings, our present data further confirm that levels of p-Erk increase in the hypothalamus following SAH. Interestingly, inhibition of Erk activation could block the increased expression of bax. These results strongly indicate the involvement of the Erk signaling pathway in the induction of apoptosis in the hypothalamus. Moreover, the increased levels of p-Erk could be blocked by neutralizing TNF-α, which further confirms the neuroprotective effect of anti-TNF-α antibody. The reduced ratios of p-Erk/Erk, accompanied by the blockade of bax, suggest that anti-TNF-α antibody protects neurons from apoptosis by inhibiting the phosphorylation of Erk. However, there are conflicting results showing the neuroprotective effect with Erk activation. Intracerebroventricular administration of brain-derived neurotrophic factor protects the neonatal rat brain from hypoxic-ischemic injury via Erk activation. 34, 35 The possible reason for the discrepancy is that the role of Erk activation may be depending on multiple signaling mechanisms. Transient Erk activation by growth factors is associated with neuroprotection, while prolonged and persistent activation induces cell death. 36 Overall, in this study, injection of anti-TNF-α antibody might have inhibited apoptosis by reducing the prolonged and persistent activation of Erk in the hypothalamus, as the levels of p-Erk were elevated 48 h after SAH.
Finally, we found that blockade of TNF-α can improve the anxiety-like behavior. A previous study has shown that increased intracranial pressure, a high-risk factor for the development of SAH, and stress play important roles in the dysfunction of the hypothalamus, 20 which is known to be involved in regulating emotional behavior. In addition, SAH is always accompanied by stress, a condition closely linked to anxiety. 37 Our open field results further confirmed that SAH could increase the levels of anxiety. Increasing evidence indicates that cytokines play a critical role in the development of neuropsychiatric disorders, including anxiety. 38, 39 TNF-α, one of the cytokines, is considered to be a key regulator in this process. 40 TNF-α expression levels were elevated both in patients with anxiety disorder and in animals with anxiety-like behavior. Consistent with these findings, TNF-α expression levels increased in the hypothalamus after SAH. Interestingly, we also found that anti-TNF-α antibody could reduce SAH-induced anxiety levels, which demonstrated the important role of TNF-α in the hypothalamus in SAH pathology. Furthermore, Karimi et al showed that intraperitoneal injection of 3,4-methylenedioxymethamphetamine increased the anxiety-like behavior and apoptotic cell numbers in the rat hippocampus, thus indicating that neuronal apoptosis may be linked to anxiety levels. 41 Due to the significant inhibition of apoptosis in response to treatment with anti-TNF-α antibody, these results further suggest that the improved anxiety-like behavior is attributed to the suppression of apoptosis in the hypothalamus. Additionally, since prolonged Erk activation can aggravate both anxietylike behavior in post-traumatic stress disordered mice 42 and apoptosis, the effective role of anti-TNF-α antibody on SAHinduced anxiety-like behavior is considered to be linked to the inhibition of p-Erk expression levels.
Limitations
Additional studies using inhibitors of apoptosis and Erk in combination with other modulators of neural apoptosis will allow us to directly elucidate their role in the hypothalamus in SAH-induced anxiety-like behavior. Moreover, since TNF-α can bind to two receptor subtypes, TNFR1 (p55-R) and TNF receptor 2 (p75-R), we next wish to examine which receptor is involved in SAH-induced apoptosis.
Conclusion
In summary, our data show that anti-TNF-α antibody blocked SAH-induced apoptosis in the hypothalamus by inhibiting the phosphorylation of Erk. Injection of anti-TNF-α antibody improved the SAH-induced anxiety-like behavior. Our findings will help to improve our understanding of the precise role of anti-TNF-α antibody in SAHinduced apoptosis. In addition, the reduced expression of apoptosis-related molecules in the hypothalamus further suggests that anti-TNF-α antibody acts at the molecular level in a regional-specific manner in the brain during the treatment of SAH.
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